Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea

Oncotarget

Volumn 8, Issue 4, 2017, Pages 7003-7013

  Kong, Doo Sik ^a   Nam, Do Hyun ^a   Kang, Shin Hyuk ^b   Lee, Jae Won ^c   Chang, Jong Hee ^d   Kim, Jeong Hoon ^e   Lim, Young Jin ^f   Koh, Young Cho ^g   Chung, Yong Gu ^b   Kim, Jae Min ^h   Kim, Choong Hyun ^h  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Korea University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Kyung Hee University College of Medicine   (South Korea)

^g Konkuk University Hospital   (South Korea)

^h Hanyang University Guri Hospital   (South Korea)

Author keywords

Autologous cytokine induced killer cell; Glioblastoma; Immunotherapy

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BACKACHE; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; CHILL; CONTROLLED STUDY; COUGHING; CYTOKINE INDUCED KILLER CELL IMMUNOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; HUMAN; HYPERSENSITIVITY; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SKIN TEST; SOUTH KOREA; URTICARIA; AUTOTRANSPLANTATION; BRAIN TUMOR; CLINICAL TRIAL; CYTOKINE INDUCED KILLER CELL; DISEASE FREE SURVIVAL; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; TEMOZOLOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85010747968     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12273     Document Type: Article

References (22)

1. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Jr. and Mehta MP. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013; 31:4085-4091.
2. Stupp R, van den Bent MJ and Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005; 5:198-206.
3. McMahon EJ, Bailey SL and Miller SD. CNS dendritic cells: critical participants in CNS inflammation? Neurochem Int. 2006; 49:195-203.
4. Wu C, Jiang J, Shi L and Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res. 2008; 28:3997-4002.
5. Wang M, Cao JX, Pan JH, Liu YS, Xu BL, Li D, Zhang XY, Li JL, Liu JL, Wang HB and Wang ZX. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. PLoS One. 2014; 9:e112662.
6. Jakel CE, Hauser S, Rogenhofer S, Muller SC, Brossart P and Schmidt-Wolf IG. Clinical studies applying cytokineinduced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol. 2012; 2012:473245.
7. Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011; 137:305-310.
8. Ma Y, Xu YC, Tang L, Zhang Z, Wang J and Wang HX. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012; 1:11.
9. Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF and Wang HX. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy. 2012; 14:483-493.
10. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M and Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012; 12:673-684.
11. Zhang Y, Xia L, Zhang Y, Wang Y, Lu X, Shi F, Liu Y, Chen M, Feng K, Zhang W, Fu X and Han W. Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers. Expert Opin Biol Ther. 2014:1-13.
12. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B and Huhn D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999; 81:1009-1016.
13. Wang ZX, Li JL, Cao JX, Liu YS, Li D, Zhang XY, Wang M, Wu M, Xu BL, Liu JL and Wang HB. Cytokine-induced killer cells in the treatment of patients with renal cell carcinoma: a pooled meta-analysis. Immunotherapy. 2014; 6:787-795.
14. Wang H, Cao F, Li J, Li Y, Liu X, Wang L, Liu Z, Li Y, Zhao H and Zhou J. Homing of cytokine-induced killer cells during the treatment of acute promyelocytic leukemia. Int J Hematol. 2014; 100:165-170.
15. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW and Yoon JH. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015; 148:1383-1391 e1386.
16. Jin J, Joo KM, Lee SJ, Jo MY, Kim Y, Jin Y, Kim JK, Ahn JM, Yoon MJ, Lim J and Nam DH. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep. 2011; 25:33-39.
17. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 356:802-807.
18. Macdonald DR, Cascino TL, Schold SC, Jr. and Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8:1277-1280.
19. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28:1963-1972.
20. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370:709-722.
21. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370:699-708.
22. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15:1100-1108.